HK1209372A1 - Low melting propionic acid derivative particles for use in oral dosage forms - Google Patents

Low melting propionic acid derivative particles for use in oral dosage forms

Info

Publication number
HK1209372A1
HK1209372A1 HK15110267.8A HK15110267A HK1209372A1 HK 1209372 A1 HK1209372 A1 HK 1209372A1 HK 15110267 A HK15110267 A HK 15110267A HK 1209372 A1 HK1209372 A1 HK 1209372A1
Authority
HK
Hong Kong
Prior art keywords
dosage forms
propionic acid
acid derivative
low melting
oral dosage
Prior art date
Application number
HK15110267.8A
Other languages
English (en)
Chinese (zh)
Inventor
‧巴格池
‧烏佩拉
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/789,797 external-priority patent/US20140256810A1/en
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Publication of HK1209372A1 publication Critical patent/HK1209372A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK15110267.8A 2012-09-18 2015-10-19 Low melting propionic acid derivative particles for use in oral dosage forms HK1209372A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702392P 2012-09-18 2012-09-18
US13/789,797 US20140256810A1 (en) 2013-03-08 2013-03-08 Low melting propionic acid derivative particles for use in oral dosage forms
PCT/US2013/059918 WO2014047001A1 (en) 2012-09-18 2013-09-16 Low melting propionic acid derivative particles for use in oral dosage forms

Publications (1)

Publication Number Publication Date
HK1209372A1 true HK1209372A1 (en) 2016-04-01

Family

ID=49231643

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15110267.8A HK1209372A1 (en) 2012-09-18 2015-10-19 Low melting propionic acid derivative particles for use in oral dosage forms
HK16100781.5A HK1212886A1 (zh) 2012-09-18 2016-01-25 用於口服劑型的低熔點丙酸衍生物粒子

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16100781.5A HK1212886A1 (zh) 2012-09-18 2016-01-25 用於口服劑型的低熔點丙酸衍生物粒子

Country Status (8)

Country Link
EP (1) EP2897584A1 (pt)
CN (1) CN104640537A (pt)
AU (1) AU2013318356A1 (pt)
BR (1) BR112015005876A2 (pt)
CA (1) CA2884119A1 (pt)
HK (2) HK1209372A1 (pt)
RU (1) RU2015114540A (pt)
WO (1) WO2014047001A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015110511A (ru) * 2014-03-28 2016-10-20 МакНЕЙЛ-ППС, ИНК. Частицы производного пропионовой кислоты для прямого прессования
CN109956860B (zh) * 2019-03-08 2022-03-01 天津大学 一种布洛芬球形晶体的制备方法
CN116211807A (zh) * 2019-11-25 2023-06-06 上海博志研新药物技术有限公司 布洛芬药物组合物、制备方法及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1497044A (en) 1974-03-07 1978-01-05 Prodotti Antibiotici Spa Salts of phenyl-alkanoic acids
DE3440288A1 (de) 1984-11-05 1986-05-07 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische zubereitung mit einem gehalt an mindestens einer schleimhautreizenden substanz oder dergleichen, insbesondere profen, sowie verfahren zu ihrer herstellung
US4923898A (en) 1984-12-26 1990-05-08 Analgesic Associates Analgesic, anti-inflammatory and skeletal muscle relaxant compositions comprising non-steroidal anti-inflammatory drugs and musculoskeletal relaxants and methods of using same
US4873231A (en) 1986-04-08 1989-10-10 Smith Walton J Decreasing the toxicity of an ibuprofen salt
CA2063141C (en) 1989-08-04 1997-03-04 Edward J. Roche Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
IT1246383B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
CA2061520C (en) 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
WO1994005260A1 (en) 1992-09-03 1994-03-17 Affinity Biotech, Inc. Taste-masking pharmaceutical compositions and methods for making the same
IT1264855B1 (it) 1993-06-21 1996-10-17 Zambon Spa Composizioni farmaceutiche contenenti sali dell'acido s(+)-2-(4-isobutilfenil) propionico con amminoacidi basici
ZA945944B (en) 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
TW442287B (en) 1995-06-13 2001-06-23 American Home Produits Corp Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac)
NZ333474A (en) 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
US6117452A (en) 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
FR2811912B1 (fr) 2000-07-21 2003-02-07 Gattefosse Ets Sa Procede d'enrobage de particules solides par un agent thermofusible, et particules solides ainsi enrobees
GB0113841D0 (en) 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
BRPI0419125A (pt) * 2004-12-10 2007-12-11 Council Scient Ind Res composição farmacêutica e processo para a preparação de uma composição farmacêutica
CN101528205A (zh) 2006-10-25 2009-09-09 麦克内尔-Ppc股份有限公司 布洛芬组合物

Also Published As

Publication number Publication date
RU2015114540A (ru) 2016-11-10
BR112015005876A2 (pt) 2017-07-04
EP2897584A1 (en) 2015-07-29
AU2013318356A1 (en) 2015-03-19
WO2014047001A1 (en) 2014-03-27
HK1212886A1 (zh) 2016-06-24
CN104640537A (zh) 2015-05-20
CA2884119A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
HK1209343A1 (en) Etanercept formulations exhibiting marked reduction in sub-visible particles
IL227383A0 (en) Extended-release oral dosage forms containing tsucitinib
EP2739288A4 (en) PROGESTERONE-CONTAINING ORAL PHARMACEUTICAL FORMS AND RELEVANT PROCEDURES
IL235425B (en) History of lysine-glutamic acid di-peptide
HRP20160989T1 (hr) Otopina za oralnu primjenu
HK1199821A1 (en) Oral pharmaceutical composition
SG11201404728VA (en) Nanoparticle paste formulations and methods for production and use thereof
HK1199822A1 (zh) 口服給藥用醫藥組合物
HK1187335A1 (en) Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals 3--
PL2726064T3 (pl) Doustna postać użytkowa o kontrolowanym uwalnianiu zawierająca oksykodon
HUE039590T2 (hu) Vegyületek koaguláció fokozásában történõ alkalmazásra
HK1215545A1 (zh) 適用於吸入治療的包含多組分結晶顆粒的藥物組合物
EP2668852A4 (en) COMPOSITION FOR ORAL ADMINISTRATION
HK1198466A1 (en) Prasugrel-containing immediate release stable oral pharmaceutical compositions
HK1212886A1 (zh) 用於口服劑型的低熔點丙酸衍生物粒子
HK1212889A1 (zh) 包含低熔點丙酸衍生物顆粒的緩釋口服劑型
ZA201502613B (en) Suspension pharmaceutical formulations comprising low melting propionic acid derivative particles
IL239975A0 (en) Pharmaceutical preparations containing multi-component crystalline particles suitable for use in inhalation therapy